Scientech Research LLC Invests $675,000 in GeneDx Holdings Corp. $WGS

Key Points

• Scientech Research LLC acquired 7,617 shares of GeneDx Holdings Corp. valued at approximately $675,000 in the 1st quarter, as reported in a recent SEC filing.
• Multiple institutional investors have increased their stakes in GeneDx, with Vanguard Group adding 25,116 shares and Summit Partners boosting its holdings by 336.9%.
• GeneDx reported a strong quarterly performance, with earnings per share (EPS) of $0.50, significantly surpassing analysts' estimates of $0.10, alongside a revenue of $102.69 million.

Scientech Research LLC bought a new stake in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 7,617 shares of the company's stock, valued at approximately $675,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in WGS. Lazard Asset Management LLC purchased a new position in GeneDx in the fourth quarter valued at about $35,000. GAMMA Investing LLC lifted its holdings in shares of GeneDx by 151.7% during the first quarter. GAMMA Investing LLC now owns 438 shares of the company's stock worth $39,000 after purchasing an additional 264 shares during the period. Comerica Bank acquired a new stake in shares of GeneDx during the fourth quarter worth about $50,000. US Bancorp DE raised its position in GeneDx by 3,223.5% during the first quarter. US Bancorp DE now owns 565 shares of the company's stock valued at $50,000 after acquiring an additional 548 shares in the last quarter. Finally, KBC Group NV purchased a new position in GeneDx during the first quarter valued at approximately $81,000. Hedge funds and other institutional investors own 61.72% of the company's stock.

Insiders Place Their Bets

In related news, Director Jason Ryan sold 38,072 shares of GeneDx stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $127.30, for a total value of $4,846,565.60. Following the sale, the director directly owned 103,284 shares in the company, valued at $13,148,053.20. The trade was a 26.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Katherine Stueland sold 2,154 shares of GeneDx stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $105.31, for a total value of $226,837.74. Following the transaction, the chief executive officer directly owned 3,440 shares of the company's stock, valued at approximately $362,266.40. This represents a 38.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 561,641 shares of company stock valued at $67,551,904 in the last three months. 29.60% of the stock is owned by corporate insiders.

GeneDx Stock Down 1.5%

Shares of NASDAQ WGS traded down $1.94 during midday trading on Friday, hitting $123.95. 311,861 shares of the company's stock were exchanged, compared to its average volume of 571,682. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.87 and a quick ratio of 2.70. GeneDx Holdings Corp. has a twelve month low of $35.88 and a twelve month high of $136.00. The company has a market cap of $3.56 billion, a PE ratio of 2,479.00 and a beta of 2.03. The firm's fifty day simple moving average is $107.63 and its 200-day simple moving average is $91.88.

GeneDx (NASDAQ:WGS - Get Free Report) last issued its earnings results on Tuesday, July 29th. The company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.40. The business had revenue of $102.69 million for the quarter, compared to analyst estimates of $86.00 million. GeneDx had a return on equity of 16.51% and a net margin of 0.39%. GeneDx has set its FY 2025 guidance at EPS. Research analysts predict that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Wells Fargo & Company raised their price target on shares of GeneDx from $78.00 to $95.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 30th. Wall Street Zen upgraded GeneDx from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Guggenheim restated a "buy" rating and issued a $115.00 target price (up from $88.00) on shares of GeneDx in a report on Monday, June 30th. Finally, Piper Sandler upped their target price on GeneDx from $120.00 to $140.00 and gave the company an "overweight" rating in a report on Thursday. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $104.13.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.